• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Ir J Med Sci . Serum calprotectin as a novel biomarker for severity of COVID-19 disease

tetano

Editor, Senior Moderator
Ir J Med Sci


. 2021 Feb 27.
doi: 10.1007/s11845-021-02565-8. Online ahead of print.
Serum calprotectin as a novel biomarker for severity of COVID-19 disease


Tezcan Kaya[SUP] 1 [/SUP], Sel?uk Yaylacı[SUP] 2 [/SUP], Ahmet Nalbant[SUP] 2 [/SUP], İlhan Yıldırım[SUP] 3 [/SUP], Havva Kocayiğit[SUP] 4 [/SUP], Erdem ?okluk[SUP] 5 [/SUP], Mehmet Ramazan Şekeroğlu[SUP] 5 [/SUP], Mehmet K?roğlu[SUP] 6 [/SUP], Ertuğrul G??l?[SUP] 7 [/SUP]



Affiliations

Abstract

Background: Some biomarkers have been reported to be related to the prognosis of the coronavirus disease 2019 (COVID-19). There are sparse data regarding the prognostic value of serum calprotectin in COVID-19 patients.
Aims: This study aimed to investigate the relationship between serum calprotectin level and clinical severity of COVID-19 disease in hospitalized patients.
Methods: This retrospective cross-sectional cohort study included 80 consecutive hospitalized patients with confirmed diagnosis of COVID-19. The study population was divided into two groups as patients hospitalized in the intensive care unit (ICU) and patients hospitalized but not in the ICU. The serum calprotectin levels, other laboratory, and clinical parameters were compared between groups.
Results: The mean age of the patients was 66.5 ? 15.7 years. Of the patients, 42 were in the ICU and 38 were not. Serum calprotectin level and acute-phase reactants such as C-reactive protein, procalcitonin, ferritin, fibrinogen, and white blood cell were significantly higher in ICU patients than in non-ICU patients. ROC curve analysis identified that serum calprotectin level was a predictor for ICU requirement with an area under the curve of 0.641 (p = 0.031). Logistic regression analysis revealed that serum calprotectin was a significant determinant for whether or not patient required the ICU.
Conclusions: These findings demonstrate that serum calprotectin level seems to be a useful biomarker that can predict the severity of COVID-19 disease. Serum calprotectin is a significant predictor of ICU requirement in patients with COVID-19.

Keywords: Biomarkers; Calprotectin; Inflammation; Intensive care unit; SARS-CoV-2.
 
Back
Top Bottom